Antiandrogen therapy in prostate cancer

Abstract

Antiandrogens are an important class of therapeutic agents for treatment of prostate cancer. While traditionally used as a second-line hormonal therapy following androgen deprivation treatment, they have been studied in a number of other settings. Antiandrogens continue to be a class of highly selective agents with relatively little toxicity compared to non-hormonal therapies for advanced disease. Compounds in development that target androgen receptor activation hold great promise for men with prostate cancer.